Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -36.94% is in line with its 5-year average of -34.84%, around the middle of its 5-year range (-48.99%–-16.41%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.29% below its 12-month average of -31.77%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -36.94%.
RETURN ON EQUITY (ROE)
-36.94%
RETURN ON EQUITY (ROE) AVG TTM
-31.77%
RETURN ON EQUITY (ROE) AVG 3Y
-37.00%
RETURN ON EQUITY (ROE) AVG 5Y
-34.84%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-16.29%
CURRENT VS 3Y AVG
+0.16%
CURRENT VS 5Y AVG
-6.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
+8.11%
vs the sector median at left
ImageneBio Inc
Market Cap
$53.80M
Return on Equity (ROE)
-36.94%
TTM Avg
-31.77%
3Y Avg
-37.00%
5Y Avg
-34.84%
Market Cap
$54.58M
Return on Equity (ROE)
-60.85%
TTM Avg
-77.57%
3Y Avg
-56.89%
5Y Avg
-53.13%
Market Cap
$54.90M
Return on Equity (ROE)
N/A
TTM Avg
171.70%
3Y Avg
384.85%
5Y Avg
251.73%
Market Cap
$52.64M
Return on Equity (ROE)
-36114.03%
TTM Avg
-31.09%
3Y Avg
-15.54%
5Y Avg
-12.44%
Market Cap
$52.46M
Return on Equity (ROE)
-52.72%
TTM Avg
-32.48%
3Y Avg
-92.81%
5Y Avg
-85.98%
Market Cap
$51.70M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
Market Cap
$51.42M
Return on Equity (ROE)
-278.89%
TTM Avg
-162.92%
3Y Avg
25.71%
5Y Avg
0.37%
Market Cap
$51.36M
Return on Equity (ROE)
-76.82%
TTM Avg
-798.41%
3Y Avg
-485.96%
5Y Avg
-324.45%
Market Cap
$50.96M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ImageneBio Inc (IMA) | $53.80M | -36.94% | -31.77% | -37.00% | -34.84% |
| Aldeyra The (ALDX)vs › | $54.58M | -60.85% | -77.57% | -56.89% | -53.13% |
| Spectral AI, Inc. (MDAI)vs › | $54.90M | N/A | 171.70% | 384.85% | 251.73% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.64M | -36114.03% | -31.09% | -15.54% | -12.44% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | -52.72% | -32.48% | -92.81% | -85.98% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.70M | N/A | 31.64% | 119.26% | -26.51% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | -278.89% | -162.92% | 25.71% | 0.37% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.36M | -76.82% | -798.41% | -485.96% | -324.45% |
| Envoy Medical, Inc. (COCH)vs › | $50.96M | -708.48% | 156.13% | 510.26% | 342.91% |
| INmune Bio, Inc. (INMB)vs › | $50.80M | -90.44% | -163.19% | -112.62% | -86.58% |
ROE
-36.9%
ROA
-34.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -36.94% |
| 2026-03-31 | -36.55% |
| 2025-12-31 | -30.44% |
| 2025-09-30 | -30.57% |
| 2025-06-30 | -24.33% |
| 2025-03-31 | -33.12% |
| 2024-12-31 | -39.10% |
| 2024-09-30 | -44.40% |
| 2024-06-30 | -46.69% |
| 2024-03-31 | -45.12% |
| 2023-12-31 | -40.16% |
| 2023-09-30 | -33.54% |
| 2023-06-30 | -40.06% |
| 2023-03-31 | -48.99% |
| 2022-12-31 | -46.79% |
| 2022-09-30 | -32.67% |
| 2022-06-30 | -28.13% |
| 2022-03-31 | -21.37% |
| 2021-12-31 | -16.41% |
| 2021-09-30 | -30.98% |
| 2021-06-30 | -25.28% |
| 2021-03-31 | -20.66% |
